Journal
JTO Clinical and Research Reports
Publication Date
1-1-2022
Volume
3
Issue
1
First Page
100262
Document Type
Open Access Publication
DOI
10.1016/j.jtocrr.2021.100262
Rights and Permissions
Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Angevin E, Hong DS, Rybkin II, Barve M, Bauer TM, Delmonte A, Dunbar M, Motwani M, Parikh A, Noon E, Wu J, Blot V, Kelly K. A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. JTO Clin Res Rep. 2021 Dec 4;3(1):100262. doi: 10.1016/j.jtocrr.2021.100262. Copyright 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
Camidge, D Ross; Morgensztern, Daniel; and et al., "A phase 1b study of telisotuzumab vedotin in combination with nivolumab in patients with NSCLC." JTO Clinical and Research Reports. 3, 1. 100262 (2022).
https://digitalcommons.wustl.edu/oa_4/3485
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
